TPST News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TP

Mkt Cap

$10.6M

Volume

65.50K

Next Earnings

November 4th

Loading chart

TP

TPSTTempest Therapeutics, Inc. Common Stock

TPST

Pay with—

Available Balance0.00

TP

Mkt Cap

$10.7M

Volume

65.50K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingTempest Therapeutics will present updated clinical data from its REDEEM-1 Phase 1/2a trial of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma, at the International Society for Cell & Gene Therapy Scientific Annual Meeting in Dublin (May 6-9, 2026). Earlier interim data showed a 100% complete response rate among six evaluable patients with a favorable safety profile.GlobeNewswire Inc. · Apr 29, 2026

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026Tempest Therapeutics selected Cincinnati Children's Applied Gene and Cell Therapy Center as its manufacturing partner for technology transfer of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma. The partnership supports preparation for a planned U.S. registrational study with IND filing targeted for Q4 2026. Recent interim data from the REDEEM-1 trial showed 100% complete response rate in all six efficacy evaluable patients and 100% overall response rate among 25 evaluable patients with measurable disease.GlobeNewswire Inc. · Mar 11, 2026

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027Tempest Therapeutics has agreed to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, which is expected to extend the company's operational runway to mid-2027 and diversify its clinical-stage pipeline.Benzinga · Nov 19, 2025

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027Tempest Therapeutics plans to acquire dual-CAR T programs from Factor Bioscience in an all-stock transaction, expanding its clinical-stage pipeline and extending its operational runway to mid-2027. The acquisition includes a clinical-stage CD19/BCMA dual-CAR T program and is expected to close in early 2026.GlobeNewswire Inc. · Nov 19, 2025

Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsightThe advanced liver cancer market is positioned for strong growth, with over 50 companies developing 52+ pipeline drugs, focusing on innovative targeted therapies and immuno-oncology combinations to improve treatment outcomes.GlobeNewswire Inc. · Sep 25, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted nonqualified stock options to one employee under its 2023 Inducement Plan. The stock options will vest over a four-year period.GlobeNewswire Inc. · Feb 7, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)Tempest Therapeutics received Orphan Drug Designation from the FDA for its drug amezalpat to treat hepatocellular carcinoma, a type of liver cancer. The drug showed promising results in a Phase 1b/2 clinical study, improving overall survival and response rates compared to the standard of care.GlobeNewswire Inc. · Jan 6, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted stock options to one employee under its 2023 Inducement Plan. The options will vest over a four-year period.GlobeNewswire Inc. · Dec 6, 2024

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Tempest Therapeutics, a clinical-stage biotechnology company, announced that it has granted stock options to two employees under its 2023 Inducement Plan. The options will vest over a four-year period, subject to continued employment.GlobeNewswire Inc. · Sep 20, 2024

$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - Archer Aviation ... - BenzingaThe article discusses recent insider trading activities in three penny stocks: Allied Gaming & Entertainment, Archer Aviation, and Tempest Therapeutics. Insiders have been aggressively buying shares in these companies, indicating their confidence in the companies' prospects.Benzinga · Jul 5, 2024

to start trading

TP

TPSTTempest Therapeutics, Inc. Common Stock

TPST

Pay with—

Available Balance0.00

Your PositionYou don't own any TPST yet.

Related Tickers

Earnings